OncoMatch/Clinical Trials/NCT06847867
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
Is NCT06847867 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies Momelotinib for myelodysplastic syndromes.
Treatment: Momelotinib — The goal of this clinical trial is to determine if momelotinib is safe and effective for people with low-risk myelodysplastic syndromes (LR-MDS). The trial will also examine how the body processes the drug. Participants will receive different doses of momelotinib to find the best dose by evaluating effectiveness in improving red blood cell transfusion requirements and safety.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Myelodysplastic Syndrome
Biomarker criteria
Excluded: 5Q deletion
MDS associated with del 5q cytogenetic abnormality
Disease stage
Required: Stage VERY LOW, LOW, INTERMEDIATE (other)
IPSS-R classification of very low, low, or intermediate risk disease, with an overall risk score ≤3.5 and bone marrow blasts < 5%
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: erythropoiesis-stimulating agent or luspatercept — LR-MDS-related anemia
Received only one prior line of treatment with either Erythropoiesis-stimulating agent (ESA) or luspatercept for LR-MDS-related anemia that is relapsed/refractory to therapy. Participants intolerant OR ineligible to prior ESA or luspatercept will fulfill this inclusion criterion provided the definition below is met.
Cannot have received: Janus kinase (JAK)1/2 inhibitor
Prior treatment with the following: Janus kinase (JAK)1/2 inhibitors
Cannot have received: ACVR1 inhibitor
Prior treatment with the following: ACVR1 inhibitors
Cannot have received: ACTRII receptor ligand trap other than luspatercept
Prior treatment with the following: ACTRII receptor ligand trap other than luspatercept
Cannot have received: hypomethylating agent
Prior treatment with the following: Hypomethylating agents
Cannot have received: immunomodulatory drug (IMiD)
Prior treatment with the following: other disease modifying agents (i.e., IMiDs)
Cannot have received: immunosuppressive therapy for MDS
Prior treatment with the following: immunosuppressive therapy for MDS
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- GSK Investigational Site · Goodyear, Arizona
- GSK Investigational Site · Duarte, California
- GSK Investigational Site · Irvine, California
- GSK Investigational Site · New Haven, Connecticut
- GSK Investigational Site · Canton, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06847867 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior Janus kinase (JAK)1/2 inhibitor, ACVR1 inhibitor, ACTRII receptor ligand trap other than luspatercept disqualifies patients from enrollment.
Are patients with 5Q alterations eligible?
No. 5Q deletion is an exclusion criterion.
What disease stage is eligible?
Stage VERY LOW or LOW or INTERMEDIATE is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages